Sulfasalazine
Azulfidine, Sulfasalazine (sulfasalazine) is a small molecule pharmaceutical. Sulfasalazine was first approved as Azulfidine on 1982-01-01. It is used to treat juvenile arthritis, rheumatoid arthritis, and ulcerative colitis in the USA. It is known to target proton-coupled folate transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Azulfidine en-tabs, Sulfasalazine (discontinued: Azulfidine, S.a.s, Sulfasalazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| azulfidine | New Drug Application | 2025-01-09 |
| sulfasalazine | NDA authorized generic | 2025-02-27 |
| sulfasalazine delayed-release | 2007-08-31 | |
| sulfazalazine | 2007-08-31 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 9 | 23 | 23 | 9 | 62 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 8 | 20 | 20 | 8 | 55 |
| Spondylarthritis | D025241 | — | — | 1 | 3 | 3 | 7 | 3 | 16 |
| Spondylitis | D013166 | — | M46.9 | 1 | 3 | 3 | 7 | 3 | 16 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | 1 | 2 | 2 | 7 | 3 | 14 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 1 | 2 | 2 | 5 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | 1 | 2 | 1 | — | 3 |
| Axial spondyloarthritis | D000089183 | — | — | — | 1 | — | 1 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | 1 | 2 |
| Diarrhea | D003967 | — | R19.7 | — | — | 1 | 1 | — | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | 1 | — | 2 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | 1 | 2 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | — | 1 | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 1 | — | 1 | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | 1 | — | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 1 |
| Spondylarthropathies | D025242 | EFO_0000706 | M47 | — | — | 1 | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic foot | D017719 | EFO_1001459 | — | — | 3 | — | — | — | 3 |
| Necrosis | D009336 | — | — | — | 1 | — | — | 1 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 1 | — | — | — | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | 1 | 2 |
| Vasculitis | D014657 | EFO_0006803 | M31 | 1 | 1 | — | — | — | 1 |
| Cryoglobulinemia | D003449 | EFO_0005846 | D89.1 | 1 | 1 | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | 1 | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 1 | — | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | 1 | 5 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Intestinal obstruction | D007415 | — | K56.60 | 2 | — | — | — | — | 2 |
| Magnetic resonance imaging | D008279 | — | — | 1 | — | — | — | — | 1 |
| Oral administration | D000284 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Vomiting | D014839 | — | R11.1 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 2 | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 2 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
| Papillomavirus infections | D030361 | — | — | — | — | — | — | 1 | 1 |
| Disease attributes | D020969 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfasalazine |
| INN | sulfasalazine |
| Description | Sulfasalazine is an azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. It has a role as a non-steroidal anti-inflammatory drug, an antiinfective agent, a gastrointestinal drug, an EC 2.5.1.18 (glutathione transferase) inhibitor, a drug allergen and a ferroptosis inducer. It is a sulfonamide, a member of pyridines and a member of azobenzenes. It is functionally related to a sulfanilamide. ... More |
| Classification | Small molecule |
| Drug class | antiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure; anti-inflammatory agents (salicylic acid derivatives); antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 599-79-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL421 |
| ChEBI ID | 9334 |
| PubChem CID | 5339 |
| DrugBank | DB00795 |
| UNII ID | 3XC8GUZ6CB (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC46A1
SLC46A1
Organism
Homo sapiens
Gene name
SLC46A1
Gene synonyms
G21, HCP1, PCFT
NCBI Gene ID
Protein name
proton-coupled folate transporter
Protein synonyms
Heme carrier protein 1, PCFT/HCP1, solute carrier family 46 (folate transporter), member 1, Solute carrier family 46 member 1
Uniprot ID
Mouse ortholog
Slc46a1 (52466)
proton-coupled folate transporter (Q9D1P1)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 38,392 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
57,709 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use